An interventional study of Fanfilcon A sphere Contact lens in Astigmatism, sponsored by CooperVision International Limited (CVIL). Not yet recruiting at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by CooperVision International Limited (CVIL) (part of CooperCompanies) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Astigmatism by CooperCompanies — 4 open to participants now, 4 under way, none of them phase 3. Astigmatism · CooperCompanies.
Among the 45 studies in Astigmatism by CooperCompanies, this one is the 30th largest by planned enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2026, is one of 44 with no phase, and was the 45th registered.
418 studies on the registry are indexed under Astigmatism; 50 are open to participants now.
Browse Astigmatism studies →4 of the 45 studies in Astigmatism by CooperCompanies are open now, in 3 countries. Recruiting first, the newest first:
CooperVision International Limited (CVIL) · Sites in United States
Ages 40+
CooperVision International Limited (CVIL) · Sites in United States, Spain
Ages 7–35
CooperVision International Limited (CVIL) · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 36 is below the median of 55 across 325 interventional studies indexed under Astigmatism.
Median enrollment 42 across the 44 interventional studies, 102 across the 1 observational. Of the 40 that completed or were terminated, 37 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CooperVision International Limited (CVIL), one of the names counted as CooperCompanies. Under that name alone:
CooperVision International Limited (CVIL) is the lead sponsor of 139 studies on the registry; 7 are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 66 (89%) have results posted.
4 of the studies in Astigmatism by CooperCompanies that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07751172CooperVision International Limited (CVIL)Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter | 2026-12 |
| NCT07940426CooperVision International Limited (CVIL)Title: Clinical Performance and Outcomes After Sphere Lens Transition | 2027-02 |
| NCT07898995CooperVision International Limited (CVIL)Clinical Performance and Outcomes After Toric Lens Transition | 2027-02 |
| NCT07829419CooperVision International Limited (CVIL)Evaluation of Two Monthly Silicone Hydrogel Multifocal Toric in Soft Contact Lens Wearers | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Astigmatism by CooperCompanies, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate subjective and clinical outcomes after transitioning from one sphere soft contact lens to another over a one-month period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- 1. Anterior segment infection, inflammation or abnormality 2. Any active anterior segment ocular disease that would contraindicate contact lens wear 3. The use of systemic or ocular medications that would contraindicate contact lens wear 4. History of herpetic keratitis 5. History of refractive surgery or irregular cornea 6. Slit lamp findings that are more serious than grade 1 (ISO scale). 7. Inactive (i.e. ghost) vessels greater than 1 mm of penetration into the cornea 8. They have corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
9. They have participated in a contact lens or contact lens care product clinical trial in the past 30 days
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Habitual wears of Confilcon A soft sphere contact lenses Refitted to Fanfilcon A sphere contact lense s and followed for one month.
Device: Fanfilcon A sphere Contact lens
Participants are refit from their habitual sphere soft contact lenses to fanfilcon A sphere contact lenses and wear the lenses for approximately one month according to the study protocol.
Subjective Comfort
Subjective comfort on insertion (0-100 Visual analogue scale)
Time frame: Baseline, 1 week, and 1 month.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.
Of 106 industry-sponsored interventional studies with no phase under Astigmatism, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 19. This study's planned 3 months is below that.
Counting every sponsor, half of 183 studies reached it within 12 months; a quarter within 4 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CooperVision International Limited (CVIL) →